Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm

Inclusion Criteria: * Male or female ≥ 18 years to 65 years; * Patients suffering from post-cholecystectomy GI-spasms in the last 3 months with symptom onset at least 6 months prior to inclusion and not requiring surgical treatment; * Laparoscopic cholecystectomy between 6 months to 5 years before enrollment; * Patients having been prescribed Duspatalin® (mebeverine) 200 mg BID (bis in die = twice a day) in accordance with approved local label; * Patient's written authorization to provide data for the program Exclusion Criteria: * General and specific contraindications to Duspatalin® treatment according to the local label; * Planned Endoscopic Retrograde Cholangiopancreatography (ERCP) and/or surgical treatment; * Being currently treated or having been treated with Duspatalin® within the 6 weeks prior to entering the program; * Pregnancy or lactation; * Other conditions that make patient participation impossible (by investigator judgment); * Previous enrollment in the present program; * Treatment with other antispasmodics, pain-medication (Nonsteroidal anti-inflammatory drugs (NSAIDs), tramadol, etc.) within 2 weeks prior to inclusion into the observational study.